Insulin Glargine: all 295 studies that test it
Page 3 of 3. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)CompletedNCT01152242Phase 1
- Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1CompletedNCT01146678Phase 1
- Various Insulin Regimens for Diabetic Inpatients With Cirrhosis TrialStatus unknownNCT01143948Phase 4
- Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 DiabetesCompletedNCT01127269Phase 4
- Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.CompletedNCT01122979Phase 4
- Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative StudyCompletedNCT01121835Phase 4
- Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral NutritionTerminatedNCT01081938Phase 4
- Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use SettingTerminatedNCT01079364Phase 4
- Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD)Status unknownNCT01035528Phase 4
- Self Titration With Apidra to Reach Target Study (START)CompletedNCT01013571Phase 4
- Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 DiabeticsCompletedNCT01002768Phase 1
- Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 DiabetesCompletedNCT00978263Not applicable
- Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 DiabetesCompletedNCT00971659Phase 1
- Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes PatientsCompletedNCT00965549Phase 4
- Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes MellitusCompletedNCT00964574Phase 4
- A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 DiabetesCompletedNCT00961324Phase 1
- Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary CareTerminatedNCT00950534Phase 4
- Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) TreatmentCompletedNCT00949442Phase 4
- Intensive Glycemic Control on Infectious Morbidity In Patients With Acute LeukemiaWithdrawnNCT00943709Phase 3
- Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes PatientsCompletedNCT00941369Phase 4
- Insulin Glargine First Line vs Metformin in Type 2 Diabetic SubjectsCompletedNCT00857870Phase 4
- Insulin Therapy in the Hospital Comparing Two ProtocolsCompletedNCT00841919Phase 4
- Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 DiabetesCompletedNCT00824668Phase 1
- Insulin Glargine Combination Therapies in Type II DiabeticsCompletedNCT00783744Phase 3
- Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKACompletedNCT00732524Phase 4
- Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic ControlCompletedNCT00701831Phase 4
- Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed InsulinCompletedNCT00693771Phase 4
- Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)CompletedNCT00659477Phase 4
- Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)CompletedNCT00653341Phase 3
- Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)CompletedNCT00653302Phase 4
- Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)CompletedNCT00642915Phase 4
- Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)TerminatedNCT00627471Phase 4
- Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 DiabetesCompletedNCT00619697Phase 4
- The Incidence of Hypoglycemia in Insulin Glargine-Treated Subjects With Diabetes Mellitus Upon Switching Between Bedtime and Morning DosingCompletedNCT00609895Phase 4
- Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 DiabetesCompletedNCT00609856Phase 4
- Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD TherapyCompletedNCT00598793Phase 3
- Extension to Study HMR1964A/3011 in BelgiumCompletedNCT00576862Phase 4
- An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical PracticeCompletedNCT00576368Phase 4
- Basal Insulins - PharmacodynamicsCompletedNCT00566124Phase 4
- Insulin Glargine, INITIATE Metabolic and Economic Outcomes of LantusCompletedNCT00565162Phase 4
- 20 Week Bridging Study in Type II DMCompletedNCT00563225Phase 3
- Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)CompletedNCT00562172Phase 4
- Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 DiabetesCompletedNCT00553020Phase 4
- Glycemic Optimization Treatment StudyCompletedNCT00552370Phase 4
- 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. GlargineCompletedNCT00551538Phase 4
- Lispro Mix 25 vs. Glargine in Type 2 DiabeticsCompletedNCT00551356Phase 3
- PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+LisproCompletedNCT00540709Phase 4
- Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics StudyCompletedNCT00539448Phase 4
- 32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes MellitusCompletedNCT00537251Phase 3
- Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline GlargineCompletedNCT00518427Phase 4
- DOMME Dose Optimization Multicentric Mexican EvaluationCompletedNCT00488527Phase 4
- One Year Glargine Treatment in CFRD Children and AdolescentsCompletedNCT00483769Phase 4
- A Comparison Between Glargine and Detemir Insulin in Type 2 DiabetesCompletedNCT00457093Not applicable
- Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 DiabetesCompletedNCT00437112Phase 3
- Lantus Versus Levemir Treat-To-TargetCompletedNCT00405418Phase 4
- A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusCompletedNCT00399724Phase 4
- Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)CompletedNCT00390728Phase 4
- Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or MetforminCompletedNCT00384215Phase 4
- A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and LantusCompletedNCT00367445Phase 4
- Prevention of Severe Hypoglycemia in Type 1 DiabetesCompletedNCT00360984Phase 4
- Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination TherapyCompletedNCT00358124Phase 4
- Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 DiabetesCompletedNCT00355849Phase 3
- Insulin Analogue With Continuous Glucose Monitoring System (CGMS) MeasurementCompletedNCT00354939Phase 4
- Lantus in PrediabetesCompletedNCT00348972Phase 1
- Insulin Glargine in Type 2 Diabetic PatientsCompletedNCT00347100Phase 4
- Lunch Time Insulin Injection by School Nurse for Poorly Controlled DiabetesCompletedNCT00340613Phase 4
- Lantus Effect on Myocardial Glucose Metabolism in T2CompletedNCT00335465Phase 4
- Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesCompletedNCT00331851Phase 3
- LANCGMS - Lantus Continuous Glucose Monitoring SubcutaneousCompletedNCT00322075Phase 4
- SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1CompletedNCT00313937Phase 4
- The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting InsulinsCompletedNCT00313742Phase 4
- Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 DiabetesCompletedNCT00312104Phase 3
- Insulin Glargine in Type 2 Diabetes MellitusCompletedNCT00311818Phase 4
- Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 DiabetesCompletedNCT00283751Phase 3
- Insulin Glargine in Type 1 Diabetes MellitusCompletedNCT00272090Phase 3
- Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic PatientsCompletedNCT00271284Phase 3
- Insulin Glargine in Type 2 DiabetesCompletedNCT00268645Phase 4
- Insulin Glargine During and After the Period of Fasting in RamadanCompletedNCT00258804Phase 4
- Insulin Glargine Vs Standard Insulin TherapyCompletedNCT00222521Phase 3
- Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 DiabetesCompletedNCT00191464Phase 4
- Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 DiabetesCompletedNCT00191178Phase 4
- Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.CompletedNCT00184626Phase 4
- Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 DiabetesCompletedNCT00184613Phase 1
- Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic PatientsCompletedNCT00174824Phase 4
- Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 DiabetesCompletedNCT00174681Phase 4
- Insulin Glulisine in Diabetes Mellitus, Type 2CompletedNCT00174668Phase 3
- LANN-study: Lantus, Amaryl, Novorapid, Novomix StudyCompletedNCT00151697Phase 3
- Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)CompletedNCT00135941Phase 3
- Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal InsulinCompletedNCT00135096Phase 3
- Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal InsulinCompletedNCT00135057Phase 3
- Comparison of Insulin Detemir With Insulin Glargine in Type 2 DiabetesCompletedNCT00106366Phase 3
- Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate TherapyCompletedNCT00099619Phase 3
- Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 DiabetesCompletedNCT00097877Phase 3
- Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 DiabetesCompletedNCT00097084Phase 3
- Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 DiabetesCompletedNCT00095082Phase 3